New possibilities of therapy and prevention of complications of infectious-inflammatory diseases of the upper respiratory tract
subject: infectious-inflammatory diseases of the upper respiratory tract, complications of chronic tonsillopharyngitis, bacterial lysates, ismigen®
description: Abstract. SARS in the overwhelming majority of cases are the initial link in the chain of pathological changes developing in acute rhinosinusitis, contribute to the severe course of the inflammatory process, development of local, remote and generalized complications. One of the important reasons for the growth of pathology of respiratory organs is increase of the prevalence of secondary immunodeficiencies (SIDS).The purpose of the study is to assess the effectiveness of the drug ISMIGEN® (sublingual tablets) on the course and severity of acute exacerbations of chronic tonsillopharyngitis during the epidemiological season of acute respiratory infections. Study design. This study is a comparative randomized, prospective, cohort trial. All patients matching the inclusion criteria and included in the study were randomized into 2 groups by 30 persons in accordance with the plan of randomization. The duration of the observation period was 6 months.Conclusions. Use of the drug Ismigen® allows significantly reduction of the likelihood of development in the patient of relapse/ exacerbation of HTF/SARS, the development of moderate and severe forms of the disease, as well as the need for additional antibiotic therapy.
creator: A. A. Krivopalov, S.V. Ryazantsev, V. A. Shatalov
source: Медицинский совет
publisher: Remedium Group LLC
date: 2016
language: RU
identifier: DOI: 10.21518/2079-701X-2016-18-24-32
coverage: Medicine